Emerging concepts in the pathophysiology of type 2 diabetes mellitus

Mount Sinai Journal of Medicine

Volumn 76, Issue 3, 2009, Pages 216-226

  Surampudi, Prasanth N ^a   John Kalarickal, Jennifer ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

cell dysfunction; Hepatic glucose output; Incretin effect; Inflammation; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN RECEPTOR; INSULIN;

CAUSAL ATTRIBUTION; CELL FUNCTION; CELL LOSS; DIABETOGENESIS; DIET RESTRICTION; DISEASE COURSE; GENETIC PREDISPOSITION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HORMONE ACTION; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; SECRETION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INCRETINS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; RISK FACTORS;

EID: 67949109691     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20113     Document Type: Review

References (97)

1. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for noninsulin dependent diabetes mellitus. The New England Journal of Medicine 1989; 321: 337-343.
2. Cavaghan M, Ehrmann D, Polonsky K. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000; 106: 329-333.
3. Stern M. Strategies and prospects for finding insulin resistance genes. J Clin Invest 2000; 323-327.
4. Polonshy K, Sturis J, Bell G. Non-insulin-dependent diabetes mellitusa genetically programmed failure of the beta cell to compensate for insulin resistance. The New England Journal of Medicine 1996; 334: 777-783.
5. Poulsen P., Ohm Kyvik K., Vaag A., Beck-Nielsen H. Heritability of Type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-a population-based twin study. Diabetologia 1999; 42(2): 139-45.
6. Poulsen P., Levin K., Beck-Nielsen H., Vaag A. Age-dependent impact of zygosity and birth weight on insulin secretion and insulin action in twins. Diabetologia 2002; 45(12): 1649-57.
7. Groop LC, Tuomi T. Non-insulin-dependent diabetes mellitus-a collision between thrifty genes and an affluent society. Ann Med 1997; 29: 37-53.
8. Condon J, Shaw JE, Luciano M, et al. A study of diabetes mellitus within a large sample of Australian twins. Twin Res Hum Genet 2008; 11(1): 28-40.
9. Froguel P, Velho G. Genetic determinants of T2DM. Recent Prog Horm Res 2001; 56: 91-105.
10. Gaulton KJ, Willer CJ, et al. Comprehensive Association Study of T2DM and Related Quantitative Traits with 222 Candidate Genes. Diabetes. 2008 Aug 4.
11. Florez JC. The Genetics of T2DM: A realistic Appraisal Circa 2008. J Clin Endocrinol Metab. 2008 Sep 9.
12. Bergvall N, Cnattingius S. Familial (shared environmental and genetic) factors and the foetal origins of cardiovascular diseases and T2DM: a review of the literature. J Intern Med. 2008.
13. Davey Smith G, Sterne JA, Tynelius P, Rasmussen F. Birth characteristics of offspring and parental diabetes: evidence for the fetal insulin hypothesis. J Epidemiol Community Health 2004; 58: 126-8.
14. Lindsay RS, Dabelea D, Roumain J, et al. T2DM and low birth weight: the role of paternal inheritance in the association of low birth weight and diabetes. Diabetes 2000; 49: 445-9.
15. Diabetes Prevention Program Research Group. Reduction in the Incidence of T2DM with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346(6): 393-403.
16. Clark D. Physical activity efficacy and effectiveness among older adults and minorities. Diabetes Care 1997; 20: 1176-1182.
17. Lee DH, Lee IK, Jin SH, et al. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2007; 30(3): 622-8.
18. Navas-Acien A, Silbergeld EK, Pastor-Barriuso R, Guallar E. Arsenic exposure and prevalence of T2DM in US adults. JAMA 2008; 300(7): 814-22.
19. Kelley D, Mintun M, Watkins S, et al. The effect of non-Insulin dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996; 97: 2705-2713.
20. Cline G, Petersen K, Krssak M, et al. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in T2DM. The New England Journal of Medicine 1999; 341: 240-246.
21. Gavi, S, Stuart, LM, Kelly, P, et al. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without T2DM. J Clin Endocrinol Metab 2007; 92: 1886.
22. Rajala MW, Scherer PE. Minireview: The Adipocyte-At the Crossroads of Energy Homeostasis, Inflammation, and Atherosclerosis. Endocrinology 2003; 144(9): 3765-3773.
23. Goldstein BJ, Scalia R. Adiponectin: A Novel Adipokine Linking Adipocytes and Vascular Function. J Clin Endocrinol Metab 2004; 89(6): 2563-2568.
24. Semple RK, Cochran EK, Soos MA, et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008; 31(5): 977-9.
25. Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and T2DM: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930.
26. Youngren JF. Regulation of insulin receptor function. Cell Mol Life Sci 2007; 64(7-8): 873-91.
27. Kadowaki T. Insights into insulin resistance and T2DM from knockout mouse models. J Clin Invest 2000; 106: 459-465.
28. Cusi K, Katsumi M, Osman A, et al. Insulin resistance differentially affects the PI-3-kinase- and MAP kinasemediated signaling in human muscle. J Clin Invest 2000; 105: 311-320.
29. Kanaya AM, Wassel Fyr C, Vittinghoff E, et al. Adipocytokines and incident diabetes mellitus in older adults: the independent effect of plasminogen activator inhibitor 1. Arch Intern Med 2006; 166: 350.
30. Zinman, B, Hanley, AJ, Harris, SB, et al. Circulating tumor necrosis factor-alpha concentrations in a Native Canadian population with high rates of T2DM mellitus. J Clin Endocrinol Metab 1999; 84: 272.
31. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610.
32. Yki-Jarvinen H. Glucose toxicity. Endocrine Rev 1992; 13: 415-431.
33. Shulman G. Cellular mechanisms of insulin resistance in humans. Am J Cardiol 1999; 83: 3J-10J.
34. Bergman R. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000; 43: 946-952.
35. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56(8): 1986.
36. Reyna SM, Ghosh S, Tantiwong P, et al. Elevated tolllike receptor 4 expression and signaling in muscle from insulin-resistant subjects. Diabetes 2008; 57(10): 2595-602.
37. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and T2DM. Nat Rev Mol Cell Biol 2008; 9(5): 367-77.
38. Okada T, Liew CW, Hu J, et al. Insulin receptors in beta-cells are critical for islet compensatory growth response to insulin resistance. Proc Natl Acad Sci U S A 2007; 104(21): 8977-82.
39. Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 2000; 23: 650-657.
40. DeFronza R, Bonadonna R, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
41. Bruce D, Chisholm D, Storlien L, Kraegen E. Physiological importance of deficiency in early prandial insulin secretion in noninsulin-dependent diabetes. Diabetes 1998; 37: 736-744.
42. Kahn S. The importance of the beta-cell in the pathogenesis of T2DM mellitus. American Journal of Medicine 2000; 108(Suppliment 6a): 2S-8S.
43. Reaven G, Chen Y, Hollenbeck C, et al. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. Journal of Clinical Endocrinology Metabolism 1993; 76: 44-48.
44. Porte DJ, Kahn S. Beta-cell dysfunction and failure in T2DM: potential mechanisms. Diabetes 2001; 50(Suppliment 1): S160-S163.
45. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulindependent) diabetes. Diabetologia 1986; 29(1): 46-52.
46. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63(2): 492-498.
47. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews 1995; 16(3): 390-410.
48. Baggio, LL and Drucker, DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132(6): 2131-2157.
49. Faerch K, Vaag A, Holst JJ, et al. Impaired fasting glycaemia vs impaired glucose tolerance: similar impairment of pancreatic alpha and beta cell function but differential roles of incretin hormones and insulin action. Diabetologia 2008; 51(5): 853-61.
50. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the Impaired Secretion of Glucagon- Like Peptide-1 in Type 2 Diabetic Patients. J Clin Endocrinol Metab 2001; 86(8): 3717-3723.
51. Drucker DJ. Enhancing Incretin Action for the Treatment of T2DM. Diabetes Care 2003; 26(10): 2929-2940.
52. Drucker DJ. Glucagon-Like Peptide-1 and the Islet {beta}-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. Endocrinology 2003; 144(12): 5145-5148.
53. Buteau J. GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008; 34(Suppl 2): S73-7.
54. Gautier JF, Fetita S, Sobngwi E, Salaün-Martin C. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with T2DM. Diabetes Metab 2005; 31(3 Pt 1): 233-242.
55. Henry R, Wallace P, Olefsky J. The effects of weight loss on the mechanims of hyperglycemia in obese noninsulin-dependent diabetes mellitus. Diabetes 1986; 35: 990-998.
56. A. Khalaileh, T. Gonen-Gross, J. Magenheim, et al. Determinants of pancreatic b-cell regeneration. Diabetes, Obesity and Metabolism 10(Suppl. 4): 2008; 128-135.
57. Tushuizen ME, Bunck MC, Pouwels PJ et al. Pancreatic Fat Content and {beta}-Cell Function in Men With and Without T2DM. Diabetes Care 2007; 30(11): 2916-2921.
58. McGarry J, Dobbins R. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999; 42: 128-138.
59. Cooper G, Day A, Willis A, et al. Amylin and the amylin gene: structure, function and relationship to islet amyloid and to diabetes mellitus. Biochimica et Biophysica Acta 1989; 1014(3): 247-258.
60. Westermark P, Johnson KH, O'Brien TD, Betsholtz C. Islet amyloid polypeptide-a novel controversy in diabetes research. Diabetologia 1992; 35(4): 297-303.
61. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in T2DM, and the toxic oligomer hypothesis. Endocr Rev. 2008; 29(3): 303-16.
62. Gastaldelli A, Baldi S, Pettiti M, et al. Influence of obesity and T2DM on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000; 49: 1367-1373.
63. Sherwin RS. Bringing light to the dark side of insulin: a journey across the blood-brain barrier. Diabetes 2008; 57(9): 2259-68.
64. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008; 29(3): 351-66.
65. Narayan KMV, Boyle JP, Thompson TJ, et al. Effect of BMI on Lifetime Risk for Diabetes in the U.S. Diabetes Care 2007; 30(6): 1562-1566.
66. Wajngot A, Chandramouli V, Schumann W, et al. Quantitative contributions of gluconeogenesis to glucose production during fasting in T2DM mellitus. Metabolism 2001; 50: 47-52.
67. Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008; 414(1): 1-18.
68. Mitrakou A, Kelley D, Veneman T et al. Contribution of abnormal muscle and liver glucose metabolism to post-prandial hyperglycemia in NIDDM. Diabetes 1990; 39(11): 1381-1390.
69. Abdul-Ghani M, DeFronzo RA. Fasting Hyperglycemia Impairs Glucose- But Not Insulin-Mediated Suppression of Glucagon Secretion. J Clin Endocrinol Metab 2007; 92(5): 1778-1784.
70. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7(8): 678-93.
71. Pehling G, Tessari P, Gerich J, et al. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest 1984; 74: 985-991.
72. Consuli A. Role of liver in pathophysiology of NIDDM. Diabetes Care 1992; 15: 430-441.
73. Unger R. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28: 574-578.
74. Reaven G, Chen Y, Godlay A, et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology Metabolism 1987; 64: 106-110.
75. Muller W, Faloona G, Aguilar-Parada E, Unger R. Abnormal ?-cell function in diabetes. Response to carbohydrate and protein ingestion. The New England Journal of Medicine 1970; 283: 109-115.
76. Dimitriadis G, Pehling G, Gerich J. Abnormal glucose modulation of islet alpha- and â-cell responses to arginine in non-insulin-dependent diabetes mellitus. Diabetes 1985; 34: 541-547.
77. Baron A, Schaeffer L, Shragg P, Kolterman O. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1897; 36: 274-283.
78. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277: E283-E290.
79. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to post-prandial hyperglycemia in subjects with type 2 diabetes mellitus. Journal of Clinical Endocrinology Metabolism 2000; 85: 4053-4059.
80. Ahren B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 2001; 44: 1998-2003.
81. Bensal P, Wang Q. Insulin as a physiological modulator of glucagon secretion. Am J Physiol Endocrinol Metab 2008.
82. Raju, B. and Cryer, P. E. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes. Diabetes 2005; 54: 757-764.
83. Gromada J, Franklin I, and Wollheim, C. B. a-Cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 2007; 28: 84-116.
84. Peterson K, Dufour S, Befroy D, et al. Impaired mitochondrial activity in the insulin-resistant offspring of patients with T2DM. NEJM 2004; 350: 664.
85. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-94.
86. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17(9): 961-9.
87. Lang IA, Galloway TS, Scarlett A, et al. Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA 2008; 300(11): 1303-10.
88. Carpenter DO. Environmental contaminants as risk factors for developing diabetes. Rev Eviron Health 2008; 23: 59-74.
89. Stahlhut RW, van Wijngaarden E, Dye TD, et al. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect 2007; 115(6): 876-82.
90. Penfornis A, Kury-Paulin S. Immunosuppressive druginduced diabetes. Diabetes Metab 2006; 32(5 Pt 2): 539-46.
91. National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics, 2007 fact sheet. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health; 2008.
92. Prevalence of diabetes among Hispanics-selected areas, 1998-2002. Morb Mortal Wkly Rep 2004; 53(40): 941-4.
93. Bennett, PH. Epidemiology of diabetes mellitus. In: Ellenberg and Rifkin's Diabetes Mellitus, Rifkin, H, Porte, D Jr (Eds.) New York: Elsevier; 1990; 363-377.
94. Carpenter DO. Environmental contaminants as risk factors for developing diabetes. Rev Eviron Health 2008; 23: 59-74.
95. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365(9467): 1333-46.
96. Narayan. Diabetes Rep 2007.
97. Malecki MT. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 68(Suppl 1): S10-21.